SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : QLT PhotoTherapeutics (QLTI)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Ian@SI who wrote (1100)10/19/2000 5:49:13 PM
From: Ian@SI  Read Replies (1) of 1321
 
I talked to Tamara today.

My letter to the Globe contained an inaccuracy.

I said, "Then there's the sheer stupidity of calling the market for Visudyne $600M US. QLT's share of Visudyne revenues will be $600M US in 2003 by the company's current estimates.".

The company's current estimate for Global Visudyne sales is in the order of $600M+ based upon the current label. That estimate doesn't include any sales which may result from the current expanded label applications or any of the other Visudyne clinical trials underway or about to be initiated.

So I may well be right that QLT's share of global Visudyne revenues will exceed $600M by 2003. However that is not the company's current estimate, nor are any analysts estimating that as unshared revenue for QLT alone.

I still expect substantial stock price upside based upon the market's traditional treatment of emerging biotechs with their first blockbuster.

Ian.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News